Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis-Reference-Cited by-同舟云学术

Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis

Published:2022-07-12 Issue:12 Volume:63 Page:2858-2868
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Harrer Dennis C.¹,Jakob Marcus²,Vogelhuber Martin¹,Lüke Florian¹³,Utpatel Kirsten⁴,Corbacioglu Selim²,Herr Wolfgang¹,Reichle Albrecht¹,Heudobler Daniel¹⁵^ORCID

Affiliation:

1. Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany

2. Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University Hospital Regensburg, Germany

3. Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany

4. Institute of Pathology, University of Regensburg, Regensburg, Germany

5. Bavarian Cancer Research Center (BZKF), University Hospital Regensburg, Regensburg, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2095627

Reference40 articles.

1. Langerhans-Cell Histiocytosis

2. Langerhans cell histiocytosis

3. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study

4. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

5. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity;Frontiers in Oncology;2024-01-11

2. Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance;Cancers;2023-12-29

3. Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer—A Step before Anakoinosis-Based Personalized Treatment;Cancers;2023-08-24

4. Multiple drugs;Reactions Weekly;2023-03-25

5. Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity;Frontiers in Oncology;2022-09-13